Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
356 Leser
Artikel bewerten:
(1)

International Institute of Business Analysis: IIBA Announces Global Leadership Changes

Finanznachrichten News

Former IIBA Board Chair Keith Ellis to Lead Engagement Strategy

PICKERING, Ontario, Feb. 17, 2021(IIBA) Board of Directors announces key changes to the global leadership team, including the appointment of a new Board Chair and Vice Chair, a new Chief Financial and Administrative Officer and the addition of a newly created executive role.

Former Board Chair Keith Ellis resigned from the association's board in December 2020. At the January 2021 board meeting, Barbara Carkenord was appointed Chair and Heather Mylan-Mains was appointed Vice Chair replacing former Vice Chair Jon Buttriss, who will remain on the board in a director capacity.

As a foundational IIBA member, Carkenord was both a contributor and expert reviewer on various versions of the globally recognized standard for business analysis, A Guide to the Business Analysis Body of Knowledge(BABOK Guide). Her focus on critical thinking and increasing business value drove her to help define the business analysis profession. She is co-founder of two successful US-based training and consulting companies and author of Seven Steps to Mastering Business Analysis, First Edition.

Board Vice Chair, Mylan-Mains is also a contributor to the BABOK Guide and is a Business Analyst Consultant and past President of the Central Iowa Chapter. She has also served as Deputy Vice President and Volunteer Vice President of IIBA Chapters in the US. She is an active speaker at business analysis conferences worldwide.

"These changes on the board reflect the dynamics of our membership association. Keith's support as Chair helped position IIBA to quickly respond to the emerging COVID-19 threat in early 2020 and, as we moved forward in the year, to provide critical leadership as we began working on a strategic plan process that will complete in early 2021. I am delighted the board has selected Barbara and Heather for their new leadership roles. They are both well known in the business analysis community from their work with IIBA Chapters and supporting the adoption of business analysis standards. I would also like to thank Jon for his work as Vice Chair and for remaining on the board in his role as director. I look forward to working together to lead IIBA's global growth and continue to shape the practice of business analysis," said Delvin Fletcher, President and CEO of IIBA.

Announcing an addition to IIBA's leadership team, Paula Pergantis, former Senior Vice President, Finance and Corporate Services at Food, Health & Consumer Products of Canada, was named as Chief Financial and Administrative Officer in October 2020. Pergantis brings an extensive background in financial and operations leadership in both the private and not-for-profit sectors to the role. Her demonstrated ability to streamline business operations that drive growth and increase efficiency will support IIBA's 2021 global strategy. Pergantis replaces former CFAO, Gail Cosman, who retired in Q4 2020.

Following his departure from the board in December, Ellis has accepted a new leadership role with IIBA. He will join IIBA in February as Chief Engagement and Growth Officer responsible for leading key areas of IIBA's global growth strategy, including strategic partnerships, organizational relationships, and membership value. In this role, Ellis will lead IIBA's Endorsed Education Provider (EEP), academic institution, and enterprise partner relationships, as well as oversee global Membership and Chapter engagement.

Ellis brings to IIBA more than 20 years of leadership experience including roles as CEO, COO, board member, investor, and mentor to various companies. He has experience with IDC, CGI, IAG Consulting, EnFocus Solutions, and Anow, among others, and co-founded and sold Digital Mosaic, a business analysis company. Ellis is a recognized voice in the business analysis community and has published and spoken extensively with the Enterprise Architecture Symposium, Business Analyst Times, Modern Analyst, and other outlets in the field in addition to his contributions to IIBA.

"Keith challenged the board to look at new ways of doing things. I am honored to take on the role of Chair and to be working with Heather as Vice Chair. The board has approved an aggressive plan to expand our presence around the world and the new CEGO role will help IIBA's leadership team focus on creating impactful opportunities to advance the global practice of business analysis," said Barbara Carkenord, CBAP, Chair IIBA Board of Directors.

"IIBA's commitment to lead the global business analysis community and professional standards starts with having the right people aligned to execute that mission. Keith is a results-oriented leader and will be a tremendous addition to the team. Paula brings a vast amount of experience to the CFAO role, impacting core business systems and analysis. We have a strong, collaborative team that I look forward to working alongside to face the opportunities before us in 2021 to support our growing community," said Fletcher.

More information about IIBA governance and senior leadership can be found at https://www.iiba.org/about-iiba/governance/.

About IIBA

International Institute of Business Analysis.

Contact

Ann Cain
Director, Communications
IIBA
ann.cain@iiba.org
+1-866-789-4422


© 2021 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.